Skip to main content
main-content
Erschienen in: Endocrine 3/2022

07.09.2022 | Original Article

Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancer

verfasst von: Haruhiko Yamazaki, Hiroyuki Iwasaki, Katsuhiko Masudo, Soji Toda, Ai Matsui, Yasushi Rino

Erschienen in: Endocrine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to analyze the clinical course of patients with differentiated thyroid cancer (DTC) who were treated by lenvatinib and investigate the specific criteria for the initiation of lenvatinib in lung metastasis.

Methods

A total of 111 patients with DTC treated by lenvatinib were included in the study. Patients were divided into two groups based on the target lesion for the initiation of lenvatinib: lung metastasis group and other metastases group.

Results

In the univariate analysis, the tumor size for the lung metastasis (p = 0.002) and the factor of lung metastasis group (p < 0.001) were significantly associated with overall survival (OS). Multivariate analysis revealed that the factor of lung metastasis group [hazard ratio, 0.408; 95% confidence interval (CI), 0.206–0.810; p = 0.010] was the only independent prognostic factor of OS. Of the 53 patients in the lung metastasis group, 12 (23%) had lung metastasis-related finding such as pleural effusion (n = 12), hemoptysis (n = 2), and dyspnea (n = 1) at the initiation of lenvatinib treatment. The median OS in patients with or without lung metastasis-related findings were 41.0 [95% CI, 10.4–not available (NA)] months and 62.9 (95% CI, 53.0–NA) months, respectively (p = 0.022).

Conclusion

Patients with lung metastasis-related finding at the initiation of lenvatinib treatment had a poorer prognosis among the lung metastasis group. It is important to consider not only the tumor size but also the presence of lung metastasis-related findings when initiating lenvatinib treatment for DTC patients with lung metastasis.
Literatur
1.
Zurück zum Zitat R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021) CrossRefPubMed R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021) CrossRefPubMed
2.
Zurück zum Zitat U. Megwalu, P.K. Moon, Thyroid cancer incidence and mortality trends in the United States: 2000–2018. Thyroid 32, 560–570 (2022) CrossRefPubMed U. Megwalu, P.K. Moon, Thyroid cancer incidence and mortality trends in the United States: 2000–2018. Thyroid 32, 560–570 (2022) CrossRefPubMed
3.
Zurück zum Zitat M.E. Cabanillas, M.A. Habra, Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat. Rev. 42, 47–55 (2016) CrossRefPubMed M.E. Cabanillas, M.A. Habra, Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat. Rev. 42, 47–55 (2016) CrossRefPubMed
4.
Zurück zum Zitat B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016) CrossRefPubMedPubMedCentral B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016) CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015) CrossRefPubMed M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015) CrossRefPubMed
6.
Zurück zum Zitat M. Tahara, N. Kiyota, A.O. Hoff, C. Badiu, T.K. Owonikoko, C.E. Dutcus, T. Suzuki, M. Ren, L.J. Wirth, Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur. J. Cancer 147, 51–57 (2021) CrossRefPubMed M. Tahara, N. Kiyota, A.O. Hoff, C. Badiu, T.K. Owonikoko, C.E. Dutcus, T. Suzuki, M. Ren, L.J. Wirth, Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur. J. Cancer 147, 51–57 (2021) CrossRefPubMed
7.
Zurück zum Zitat N. Kiyota, M. Tahara, B. Robinson, M. Schlumberger, S.I. Sherman, S. Leboulleux, E.K. Lee, T. Suzuki, M. Ren, K. Fushimi, L.J. Wirth, Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer 128, 2281–2287 (2022) CrossRefPubMed N. Kiyota, M. Tahara, B. Robinson, M. Schlumberger, S.I. Sherman, S. Leboulleux, E.K. Lee, T. Suzuki, M. Ren, K. Fushimi, L.J. Wirth, Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer 128, 2281–2287 (2022) CrossRefPubMed
8.
Zurück zum Zitat M.H. Taylor, S. Takahashi, J. Capdevila, M. Tahara, S. Leboulleux, N. Kiyota, C.E. Dutcus, R. Xie, B. Robinson, S. Sherman, M.A. Habra, R. Elisei, L.J. Wirth, Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 31, 1226–1234 (2021) CrossRefPubMedPubMedCentral M.H. Taylor, S. Takahashi, J. Capdevila, M. Tahara, S. Leboulleux, N. Kiyota, C.E. Dutcus, R. Xie, B. Robinson, S. Sherman, M.A. Habra, R. Elisei, L.J. Wirth, Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 31, 1226–1234 (2021) CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat N. Kiyota, M. Schlumberger, K. Muro, Y. Ando, S. Takahashi, Y. Kawai, L. Wirth, B. Robinson, S. Sherman, T. Suzuki, K. Fujino, A. Gupta, S. Hayato, M. Tahara, Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 106, 1714–1721 (2015) CrossRefPubMedPubMedCentral N. Kiyota, M. Schlumberger, K. Muro, Y. Ando, S. Takahashi, Y. Kawai, L. Wirth, B. Robinson, S. Sherman, T. Suzuki, K. Fujino, A. Gupta, S. Hayato, M. Tahara, Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 106, 1714–1721 (2015) CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat H. Iwasaki, S. Toda, D. Murayama, A. Matsui, Analysis of disease progression and prognosis in differentiated thyroid cancer with pulmonary metastases: a retrospective study. Int. J. Surg. Oncol. 5, e104 (2020) CrossRef H. Iwasaki, S. Toda, D. Murayama, A. Matsui, Analysis of disease progression and prognosis in differentiated thyroid cancer with pulmonary metastases: a retrospective study. Int. J. Surg. Oncol. 5, e104 (2020) CrossRef
11.
Zurück zum Zitat H. Yamazaki, H. Iwasaki, H. Takasaki, N. Suganuma, R. Sakai, K. Masudo, H. Nakayama, Y. Rino, M. Masuda, Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer. Medicine 98, e14774 (2019) CrossRefPubMedPubMedCentral H. Yamazaki, H. Iwasaki, H. Takasaki, N. Suganuma, R. Sakai, K. Masudo, H. Nakayama, Y. Rino, M. Masuda, Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer. Medicine 98, e14774 (2019) CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009) CrossRefPubMed E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009) CrossRefPubMed
13.
Zurück zum Zitat Y. Kanda, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 48, 452–458 (2013) CrossRef Y. Kanda, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 48, 452–458 (2013) CrossRef
14.
Zurück zum Zitat A.G. Gianoukakis, C.E. Dutcus, N. Batty, M. Guo, M. Baig, Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr. Relat. Cancer 25, 699–704 (2018) CrossRefPubMedPubMedCentral A.G. Gianoukakis, C.E. Dutcus, N. Batty, M. Guo, M. Baig, Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr. Relat. Cancer 25, 699–704 (2018) CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat M.S. Brose, F.P. Worden, K.L. Newbold, M. Guo, A. Hurria, Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J. Clin. Oncol. 35, 2692–2699 (2017) CrossRefPubMed M.S. Brose, F.P. Worden, K.L. Newbold, M. Guo, A. Hurria, Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J. Clin. Oncol. 35, 2692–2699 (2017) CrossRefPubMed
16.
Zurück zum Zitat D. Wu, C.J. Gomes Lima, S.L. Moreau, K. Kulkarni, A. Zeymo, K.D. Burman, L. Wartofsky, D. Van Nostrand, Improved survival after multimodal approach with 131 I treatment in patients with bone metastases secondary to differentiated thyroid cancer. Thyroid 29, 971–978 (2019) CrossRefPubMed D. Wu, C.J. Gomes Lima, S.L. Moreau, K. Kulkarni, A. Zeymo, K.D. Burman, L. Wartofsky, D. Van Nostrand, Improved survival after multimodal approach with 131 I treatment in patients with bone metastases secondary to differentiated thyroid cancer. Thyroid 29, 971–978 (2019) CrossRefPubMed
17.
Zurück zum Zitat Y. Saito, K. Sugino, H. Takami, K. Matsuzu, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, H. Kawakubo, K. Ito, Y. Kitagawa, Clinical status and treatment of liver metastasis of differentiated thyroid cancer using tyrosine kinase inhibitors. World J. Surg. 42, 3632–3637 (2018) CrossRefPubMed Y. Saito, K. Sugino, H. Takami, K. Matsuzu, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, H. Kawakubo, K. Ito, Y. Kitagawa, Clinical status and treatment of liver metastasis of differentiated thyroid cancer using tyrosine kinase inhibitors. World J. Surg. 42, 3632–3637 (2018) CrossRefPubMed
18.
Zurück zum Zitat F. Saito, T. Uruno, H. Shibuya, W. Kitagawa, M. Nagahama, K. Sugino, K. Ito, Prognosis after brain metastasis from differentiated thyroid carcinoma. World J. Surg. 40, 574–581 (2016) CrossRefPubMed F. Saito, T. Uruno, H. Shibuya, W. Kitagawa, M. Nagahama, K. Sugino, K. Ito, Prognosis after brain metastasis from differentiated thyroid carcinoma. World J. Surg. 40, 574–581 (2016) CrossRefPubMed
19.
Zurück zum Zitat D.T. Broome, G.B. Gadre, E. Fayazzadeh, J.F. Bena, C. Nasr, Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma. Endocr. Connect 9, 812–823 (2020) CrossRefPubMedPubMedCentral D.T. Broome, G.B. Gadre, E. Fayazzadeh, J.F. Bena, C. Nasr, Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma. Endocr. Connect 9, 812–823 (2020) CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat H. Yamazaki, K. Sugino, K. Matsuzu, C. Masaki, J. Akaishi, K. Hames, C. Tomoda, A. Suzuki, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, M. Masuda, K. Ito, Rapid disease progression after discontinuation of lenvatinib in thyroid cancer. Medicine 99, e19408 (2020) CrossRefPubMedPubMedCentral H. Yamazaki, K. Sugino, K. Matsuzu, C. Masaki, J. Akaishi, K. Hames, C. Tomoda, A. Suzuki, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, M. Masuda, K. Ito, Rapid disease progression after discontinuation of lenvatinib in thyroid cancer. Medicine 99, e19408 (2020) CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat K. Sugino, M. Nagahama, W. Kitagawa, K. Ohkuwa, T. Uruno, K. Matsuzu, A. Suzuki, C. Masaki, J. Akaishi, K.Y. Hames, C. Tomoda, Y. Ogimi, K. Ito, Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocr. J. 65, 299–306 (2018) CrossRefPubMed K. Sugino, M. Nagahama, W. Kitagawa, K. Ohkuwa, T. Uruno, K. Matsuzu, A. Suzuki, C. Masaki, J. Akaishi, K.Y. Hames, C. Tomoda, Y. Ogimi, K. Ito, Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocr. J. 65, 299–306 (2018) CrossRefPubMed
22.
Zurück zum Zitat M.E. Cabanillas, M. Schlumberger, B. Jarzab, R.G. Martins, F. Pacini, B. Robinson, J.C. McCaffrey, M.H. Shah, D.L. Bodenner, D. Topliss, C. Andresen, J.P. O’Brien, M. Ren, Y. Funahashi, R. Allison, R. Elisei, K. Newbold, L.F. Licitra, S.I. Sherman, D.W. Ball, A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121, 2749–2756 (2015) CrossRefPubMed M.E. Cabanillas, M. Schlumberger, B. Jarzab, R.G. Martins, F. Pacini, B. Robinson, J.C. McCaffrey, M.H. Shah, D.L. Bodenner, D. Topliss, C. Andresen, J.P. O’Brien, M. Ren, Y. Funahashi, R. Allison, R. Elisei, K. Newbold, L.F. Licitra, S.I. Sherman, D.W. Ball, A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121, 2749–2756 (2015) CrossRefPubMed
23.
Zurück zum Zitat M.S. Brose, Y. Panaseykin, B. Konda, C. de la Fouchardiere, B.G.M. Hughes, A.G. Gianoukakis, Y. Joo Park, I. Romanov, M.K. Krzyzanowska, S. Leboulleux, T.A. Binder, C. Dutcus, R. Xie, M.H. Taylor, A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 107, 776–787 (2020) CrossRef M.S. Brose, Y. Panaseykin, B. Konda, C. de la Fouchardiere, B.G.M. Hughes, A.G. Gianoukakis, Y. Joo Park, I. Romanov, M.K. Krzyzanowska, S. Leboulleux, T.A. Binder, C. Dutcus, R. Xie, M.H. Taylor, A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 107, 776–787 (2020) CrossRef
24.
Zurück zum Zitat E. Song, M. Kim, E.Y. Kim, B.H. Kim, D.Y. Shin, H.C. Kang, B.C. Ahn, W.B. Kim, Y.K. Shong, M.J. Jeon, D.J. Lim, Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 30, 732–738 (2020) CrossRefPubMed E. Song, M. Kim, E.Y. Kim, B.H. Kim, D.Y. Shin, H.C. Kang, B.C. Ahn, W.B. Kim, Y.K. Shong, M.J. Jeon, D.J. Lim, Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 30, 732–738 (2020) CrossRefPubMed
25.
Zurück zum Zitat H.J. Jiang, Y.H. Chang, Y.H. Chen, C.W. Wu, P.W. Wang, P.J. Hsiao, Low dose of lenvatinib treatment for patients of radioiodine-refractory differentiated thyroid carcinoma—a real-world experience. Cancer Manag. Res. 13, 7139–7148 (2021) CrossRefPubMedPubMedCentral H.J. Jiang, Y.H. Chang, Y.H. Chen, C.W. Wu, P.W. Wang, P.J. Hsiao, Low dose of lenvatinib treatment for patients of radioiodine-refractory differentiated thyroid carcinoma—a real-world experience. Cancer Manag. Res. 13, 7139–7148 (2021) CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat T. Ozeki, M. Nagahama, K. Fujita, A. Suzuki, K. Sugino, K. Ito, M. Miura, Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci. Rep. 9, 5404 (2019) CrossRefPubMedPubMedCentral T. Ozeki, M. Nagahama, K. Fujita, A. Suzuki, K. Sugino, K. Ito, M. Miura, Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci. Rep. 9, 5404 (2019) CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat M. Nagahama, T. Ozeki, A. Suzuki, K. Sugino, T. Niioka, K. Ito, M. Miura, Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol. 36, 39 (2019) CrossRefPubMed M. Nagahama, T. Ozeki, A. Suzuki, K. Sugino, T. Niioka, K. Ito, M. Miura, Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol. 36, 39 (2019) CrossRefPubMed
28.
Zurück zum Zitat H. Iwamoto, H. Suzuki, S. Shimose, T. Niizeki, M. Nakano, T. Shirono, S. Okamura, Y. Noda, N. Kamachi, T. Nakamura, A. Masuda, T. Sakaue, T. Tanaka, D. Nakano, M. Sakai, T. Yamaguchi, R. Kuromatsu, H. Koga, T. Torimura, Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers 12, 1010 (2020) CrossRefPubMedCentral H. Iwamoto, H. Suzuki, S. Shimose, T. Niizeki, M. Nakano, T. Shirono, S. Okamura, Y. Noda, N. Kamachi, T. Nakamura, A. Masuda, T. Sakaue, T. Tanaka, D. Nakano, M. Sakai, T. Yamaguchi, R. Kuromatsu, H. Koga, T. Torimura, Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers 12, 1010 (2020) CrossRefPubMedCentral
29.
Zurück zum Zitat M. Tahara, M. Schlumberger, R. Elisei, M.A. Habra, N. Kiyota, R. Paschke, C.E. Dutcus, T. Hihara, S. McGrath, M. Matijevic, T. Kadowaki, Y. Funahashi, S.I. Sherman, Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur. J. Cancer 75, 213–221 (2017) CrossRefPubMed M. Tahara, M. Schlumberger, R. Elisei, M.A. Habra, N. Kiyota, R. Paschke, C.E. Dutcus, T. Hihara, S. McGrath, M. Matijevic, T. Kadowaki, Y. Funahashi, S.I. Sherman, Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur. J. Cancer 75, 213–221 (2017) CrossRefPubMed
30.
Zurück zum Zitat H. Yamazaki, T. Yokose, H. Hayashi, H. Iwasaki, S. Osanai, N. Suganuma, H. Nakayama, K. Masudo, Y. Rino, M. Masuda, Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study. Eur. J. Clin. Pharm. 76, 703–709 (2020) CrossRef H. Yamazaki, T. Yokose, H. Hayashi, H. Iwasaki, S. Osanai, N. Suganuma, H. Nakayama, K. Masudo, Y. Rino, M. Masuda, Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study. Eur. J. Clin. Pharm. 76, 703–709 (2020) CrossRef
Metadaten
Titel
Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancer
verfasst von
Haruhiko Yamazaki
Hiroyuki Iwasaki
Katsuhiko Masudo
Soji Toda
Ai Matsui
Yasushi Rino
Publikationsdatum
07.09.2022
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03183-9

Weitere Artikel der Ausgabe 3/2022

Endocrine 3/2022 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.